ArticleThe oncologist2025

Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study.

Carmine Valenza et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.